| Project/Area Number |
19590162
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Tokyo University of Pharmacy and Life Science |
|---|
Principal Investigator |
HIRANO Toshihiko Tokyo University of Pharmacy and Life Science, 薬学部, 教授 (90173252)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MATSUNO Naoto 東京医科大学, 医学部, 准教授 (00231598)
|
|---|
| Project Period (FY) |
2007 – 2009
|
| Project Status |
Completed (Fiscal Year 2009)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2009: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2008: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2007: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | スーパー抗原 / 末梢血リンパ球 / 免疫抑制薬 / 薬物耐性機序 / 抗菌薬 / ヒト末梢血単核細胞 / インターロイキンー2 / 溶血性連鎖球菌 / カテプシン / ペプスタチン / ロキシスロマイシン / 免疫抑制薬耐性の分子機序 / インターロイキン-2 / ビタミンD3誘導体 / グルココルチコイド / MAPキナーゼ / JNK |
|---|
| Research Abstract |
Immunosuppressive drugs are used for treatment of several autoimmune diseases, whereas some of the patients are known to show resistance to the therapeutic efficacy of the drugs. I showed in the present study that superantigen produced from infectious bacteria aggressively stimulate immune cells, which results in production of high amount of interleukin-2 (IL-2) and the drug resistance. I also found that roxithromycin can suppress the IL-2 production from superantigen-stimulated immune cells, and therefore the drug may overcome clinical resistance to immunosuppressive drugs in patients with autoimmune diseases having bacterial infection.
|
